BRPI0620187A2 - método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit - Google Patents

método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit Download PDF

Info

Publication number: BRPI0620187A2
Authority: BR; Brazil
Prior art keywords: lymphocytes; tumor; reactive; day; culture medium
Prior art date: 2005-12-21

Application number

BRPI0620187-3A

Other languages

English (en)

Portuguese (pt)

Inventor

Ola Winqvist

Magnus Thoern

Original Assignee

Sentoclone Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2006-12-20

Publication date

2011-11-01

2006-12-20 Application filed by Sentoclone Ab filed Critical Sentoclone Ab

2006-12-20 Priority claimed from PCT/EP2006/012304 external-priority patent/WO2007071388A1/en

2011-11-01 Publication of BRPI0620187A2 publication Critical patent/BRPI0620187A2/pt

Links

210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 256
206010028980 Neoplasm Diseases 0.000 title claims abstract description 237
238000000034 method Methods 0.000 title claims abstract description 117
210000002443 helper t lymphocyte Anatomy 0.000 title claims abstract description 47
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
201000010099 disease Diseases 0.000 title claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
230000001613 neoplastic effect Effects 0.000 title claims description 5
239000000126 substance Substances 0.000 claims abstract description 123
239000000427 antigen Substances 0.000 claims abstract description 71
102000036639 antigens Human genes 0.000 claims abstract description 71
108091007433 antigens Proteins 0.000 claims abstract description 71
230000000694 effects Effects 0.000 claims abstract description 49
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract description 41
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract description 41
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract description 41
238000011161 development Methods 0.000 claims abstract description 35
108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract description 24
102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 24
239000000556 agonist Substances 0.000 claims abstract description 19
230000001737 promoting effect Effects 0.000 claims abstract description 19
230000001105 regulatory effect Effects 0.000 claims abstract description 14
239000003550 marker Substances 0.000 claims abstract description 8
230000003213 activating effect Effects 0.000 claims abstract description 7
230000004083 survival effect Effects 0.000 claims abstract description 5
239000002458 cell surface marker Substances 0.000 claims abstract description 4
230000012010 growth Effects 0.000 claims abstract description 4
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 66
239000001963 growth medium Substances 0.000 claims description 59
210000001165 lymph node Anatomy 0.000 claims description 34
108010074328 Interferon-gamma Proteins 0.000 claims description 29
108010002350 Interleukin-2 Proteins 0.000 claims description 28
102000000588 Interleukin-2 Human genes 0.000 claims description 28
239000002609 medium Substances 0.000 claims description 28
102100037850 Interferon gamma Human genes 0.000 claims description 27
108010065805 Interleukin-12 Proteins 0.000 claims description 25
102000013462 Interleukin-12 Human genes 0.000 claims description 25
229940044601 receptor agonist Drugs 0.000 claims description 25
239000000018 receptor agonist Substances 0.000 claims description 25
108090000765 processed proteins & peptides Proteins 0.000 claims description 21
210000000612 antigen-presenting cell Anatomy 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 19
102000004196 processed proteins & peptides Human genes 0.000 claims description 18
102000004388 Interleukin-4 Human genes 0.000 claims description 16
108090000978 Interleukin-4 Proteins 0.000 claims description 16
230000003042 antagnostic effect Effects 0.000 claims description 15
108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims description 15
230000003472 neutralizing effect Effects 0.000 claims description 13
108010002616 Interleukin-5 Proteins 0.000 claims description 12
206010027476 Metastases Diseases 0.000 claims description 12
210000000447 Th1 cell Anatomy 0.000 claims description 12
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 12
230000009401 metastasis Effects 0.000 claims description 11
102100025137 Early activation antigen CD69 Human genes 0.000 claims description 10
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 10
102000004527 Interleukin-21 Receptors Human genes 0.000 claims description 10
108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 10
102000003814 Interleukin-10 Human genes 0.000 claims description 9
108090000174 Interleukin-10 Proteins 0.000 claims description 9
102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 9
108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 9
108010002586 Interleukin-7 Proteins 0.000 claims description 9
102000000704 Interleukin-7 Human genes 0.000 claims description 9
230000001965 increasing effect Effects 0.000 claims description 9
229920001184 polypeptide Polymers 0.000 claims description 9
108010017515 Interleukin-12 Receptors Proteins 0.000 claims description 8
230000003828 downregulation Effects 0.000 claims description 8
210000001616 monocyte Anatomy 0.000 claims description 8
210000005259 peripheral blood Anatomy 0.000 claims description 8
239000011886 peripheral blood Substances 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
230000004936 stimulating effect Effects 0.000 claims description 8
102000003812 Interleukin-15 Human genes 0.000 claims description 7
108090000172 Interleukin-15 Proteins 0.000 claims description 7
102000010782 Interleukin-7 Receptors Human genes 0.000 claims description 7
108010038498 Interleukin-7 Receptors Proteins 0.000 claims description 7
210000003719 b-lymphocyte Anatomy 0.000 claims description 7
210000003162 effector t lymphocyte Anatomy 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
102000001617 Interferon Receptors Human genes 0.000 claims description 6
108010054267 Interferon Receptors Proteins 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 6
-1 e.g. e.g. AIMY Substances 0.000 claims description 6
210000000265 leukocyte Anatomy 0.000 claims description 6
239000012980 RPMI-1640 medium Substances 0.000 claims description 5
210000003071 memory t lymphocyte Anatomy 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 4
239000012679 serum free medium Substances 0.000 claims description 4
MRKKUGDWODATMF-SECBINFHSA-N (2R)-2-[[5-methoxy-2-(methylamino)pyrimidin-4-yl]amino]hexan-1-ol Chemical compound CCCC[C@H](CO)Nc1nc(NC)ncc1OC MRKKUGDWODATMF-SECBINFHSA-N 0.000 claims description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 claims description 3
229940124257 Interferon receptor agonist Drugs 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
239000007758 minimum essential medium Substances 0.000 claims description 3
210000000813 small intestine Anatomy 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
230000008685 targeting Effects 0.000 claims description 3
201000009030 Carcinoma Diseases 0.000 claims description 2
208000023661 Haematological disease Diseases 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
206010043276 Teratoma Diseases 0.000 claims description 2
210000000988 bone and bone Anatomy 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
208000035269 cancer or benign tumor Diseases 0.000 claims description 2
210000003679 cervix uteri Anatomy 0.000 claims description 2
210000001072 colon Anatomy 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
238000007710 freezing Methods 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
210000001503 joint Anatomy 0.000 claims description 2
201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 2
238000012544 monitoring process Methods 0.000 claims description 2
210000003205 muscle Anatomy 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims description 2
210000002435 tendon Anatomy 0.000 claims description 2
210000003932 urinary bladder Anatomy 0.000 claims description 2
210000003905 vulva Anatomy 0.000 claims description 2
102000004560 Interleukin-12 Receptors Human genes 0.000 claims 3
239000003814 drug Substances 0.000 claims 1
210000004698 lymphocyte Anatomy 0.000 abstract description 80
230000004913 activation Effects 0.000 abstract description 44
230000001976 improved effect Effects 0.000 abstract description 4
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 59
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 32
230000018109 developmental process Effects 0.000 description 19
229940117681 interleukin-12 Drugs 0.000 description 18
206010027457 Metastases to liver Diseases 0.000 description 17
201000011510 cancer Diseases 0.000 description 17
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 11
108090000695 Cytokines Proteins 0.000 description 11
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
238000001356 surgical procedure Methods 0.000 description 10
238000004113 cell culture Methods 0.000 description 9
208000029742 colonic neoplasm Diseases 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
210000003289 regulatory T cell Anatomy 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
206010003445 Ascites Diseases 0.000 description 8
206010009944 Colon cancer Diseases 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
230000008034 disappearance Effects 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
230000000977 initiatory effect Effects 0.000 description 7
239000003446 ligand Substances 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
238000002271 resection Methods 0.000 description 7
238000000684 flow cytometry Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
238000003306 harvesting Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
210000000822 natural killer cell Anatomy 0.000 description 6
210000005005 sentinel lymph node Anatomy 0.000 description 6
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
102000000743 Interleukin-5 Human genes 0.000 description 5
108091008874 T cell receptors Proteins 0.000 description 5
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000032823 cell division Effects 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000007858 starting material Substances 0.000 description 5
101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
102000008100 Human Serum Albumin Human genes 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
108010063738 Interleukins Proteins 0.000 description 4
102100033467 L-selectin Human genes 0.000 description 4
206010027458 Metastases to lung Diseases 0.000 description 4
210000004241 Th2 cell Anatomy 0.000 description 4
102000040945 Transcription factor Human genes 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000002591 computed tomography Methods 0.000 description 4
230000003750 conditioning effect Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000001926 lymphatic effect Effects 0.000 description 4
210000000713 mesentery Anatomy 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 3
108010004729 Phycoerythrin Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
210000004443 dendritic cell Anatomy 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000011835 investigation Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000037361 pathway Effects 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000002965 ELISA Methods 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
230000033289 adaptive immune response Effects 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
239000001045 blue dye Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000005859 cell recognition Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012997 ficoll-paque Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
238000007453 hemicolectomy Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
101100407150 Arabidopsis thaliana PBL5 gene Proteins 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
208000006478 Cecal Neoplasms Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
206010016807 Fluid retention Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
229940124753 IL-2 agonist Drugs 0.000 description 1
102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
201000011024 colonic benign neoplasm Diseases 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
238000007489 histopathology method Methods 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000037451 immune surveillance Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
208000022766 lymph node neoplasm Diseases 0.000 description 1
230000005427 lymphocyte apoptotic process Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
229940087463 proleukin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
210000005212 secondary lymphoid organ Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000001599 sigmoid colon Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000013595 supernatant sample Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0620187-3A 2005-12-21 2006-12-20 método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit BRPI0620187A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US75282805P	2005-12-21	2005-12-21
DKPA200501810		2005-12-21
DKPA200501810		2005-12-21
US60/752828		2005-12-21
PCT/EP2006/012304 WO2007071388A1 (en)	2005-12-21	2006-12-20	Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer

Publications (1)

Publication Number	Publication Date
BRPI0620187A2 true BRPI0620187A2 (pt)	2011-11-01

Family

ID=36763835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0620187-3A BRPI0620187A2 (pt)	2005-12-21	2006-12-20	método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit

Country Status (5)

Country	Link
CN (1)	CN101346463B (de)
AT (1)	ATE483470T1 (de)
BR (1)	BRPI0620187A2 (de)
DE (1)	DE602006017435D1 (de)
NZ (1)	NZ569105A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015100495A1 (en) *	2014-01-03	2015-07-09	FullHope Biomedical Co., Ltd.	Modified natural killer cells, compositions and uses thereof
ES2738705T3 (es) *	2014-09-19	2020-01-24	Hope City	Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
GB201519340D0 (en) *	2015-11-02	2015-12-16	Cambridge Entpr Ltd	Methods of T-lymphocyte expansion
CN105586312A (zh) *	2016-02-29	2016-05-18	时宏珍	Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
SG11201900442PA (en) *	2016-07-21	2019-02-27	Berkeley Lights Inc	Sorting of t lymphocytes in a microfluidic device
CN106754703B (zh) *	2016-12-26	2018-03-16	浙江丹晖生物科技有限公司	一种til细胞体外扩增培养基组合和培养方法
US11293924B2 (en) *	2017-02-07	2022-04-05	Saitama Medical University	Immunological biomarker for predicting clinical effect of cancer
JP7606225B2 (ja)	2019-02-20	2024-12-25	学校法人埼玉医科大学	放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー

2006
- 2006-12-20 AT AT06841050T patent/ATE483470T1/de not_active IP Right Cessation
- 2006-12-20 CN CN2006800487393A patent/CN101346463B/zh active Active
- 2006-12-20 DE DE602006017435T patent/DE602006017435D1/de active Active
- 2006-12-20 NZ NZ569105A patent/NZ569105A/en not_active IP Right Cessation
- 2006-12-20 BR BRPI0620187-3A patent/BRPI0620187A2/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN101346463A (zh)	2009-01-14
NZ569105A (en)	2011-07-29
DE602006017435D1 (de)	2010-11-18
ATE483470T1 (de)	2010-10-15
CN101346463B (zh)	2012-06-13

Legal Events

Date	Code	Title	Description
2012-04-10	B06F	Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
2013-04-16	B08F	Application fees: dismissal - article 86 of industrial property law	Free format text: REFERENTE A 6A ANUIDADE.
2013-08-27	B08K	Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.

Publication	Publication Date	Title
CA2634167C (en)	2015-06-16	Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en)	2011-05-31	Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
US8007785B2 (en)	2011-08-30	Method for treating colon cancer with tumour-reactive T-lymphocytes
CN101351546B (zh)	2013-05-29	治疗播散性癌症的方法
AU2006328945B2 (en)	2011-06-30	Method for treating malignant melanoma
Fujiwara et al.	2012	Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer
Schwinger et al.	2005	Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
Ramanathan et al.	2014	Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study
Sakakibara et al.	2011	Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide
Dillman et al.	2007	Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma
CN101346463B (zh)	2012-06-13	用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法
US8101173B2 (en)	2012-01-24	Method for treating urinary bladder cancer
Rueda et al.	1996	Interleukin-2 in neuroblastoma: Clinical perspectives based on biological studies
Koide et al.	2009	Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70
Parrado	2021	Characterization of mechanisms that compromise dendritic cell function in melanoma